Class information for:
Level 1: BEVACIZUMAB//OVARIAN CANCER//VEGF TRAP

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
14480 767 44.2 84%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
518 3       ANGIOGENESIS//RETINOPATHY OF PREMATURITY//ENDOSTATIN 20826
361 2             ANGIOGENESIS//ENDOSTATIN//VEGF 17372
14480 1                   BEVACIZUMAB//OVARIAN CANCER//VEGF TRAP 767

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 BEVACIZUMAB authKW 362370 25% 5% 190
2 OVARIAN CANCER authKW 298335 39% 3% 296
3 VEGF TRAP authKW 114675 1% 26% 11
4 AFLIBERCEPT authKW 102347 3% 10% 25
5 GASTROINTESTINAL PERFORATION authKW 98746 2% 18% 14
6 GYNECOL ONCOL address 94814 21% 1% 163
7 RECURRENT OVARIAN CANCER authKW 83563 3% 10% 21
8 HLTH HOSP CLIN address 79620 0% 100% 2
9 TREBANANIB authKW 75421 1% 32% 6
10 RECURRENT EPITHELIAL OVARIAN CANCER authKW 71083 1% 36% 5

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 16645 75% 0% 574
2 Obstetrics & Gynecology 5228 25% 0% 194
3 Pharmacology & Pharmacy 126 10% 0% 77
4 Pathology 50 3% 0% 23
5 Medicine, Research & Experimental 36 4% 0% 29
6 Hematology 15 2% 0% 17
7 Reproductive Biology 3 1% 0% 6
8 Surgery 2 3% 0% 26
9 Biotechnology & Applied Microbiology 1 2% 0% 17
10 Gastroenterology & Hepatology 1 1% 0% 9

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 GYNECOL ONCOL 94814 21% 1% 163
2 HLTH HOSP CLIN 79620 0% 100% 2
3 GLOBAL DEV ONCOL 53079 0% 67% 2
4 NHS ONCOL 53079 0% 67% 2
5 SUTTER CANC 53079 0% 67% 2
6 UMR 37 38 53079 0% 67% 2
7 ST JOSEPHS HOSP MED 44999 1% 10% 11
8 AGO AUSTRIA 39810 0% 100% 1
9 AGO OVARIAN CANC STUDY GRP AGO 39810 0% 100% 1
10 AUSTRALIA NEW ZEALAND GYNAECOL ONCOL GRP 39810 0% 100% 1

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 GYNECOLOGIC ONCOLOGY 48051 15% 1% 117
2 INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 8567 4% 1% 31
3 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 3282 2% 1% 13
4 CLINICAL CANCER RESEARCH 2376 4% 0% 30
5 EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY 2282 2% 0% 13
6 EXPERT OPINION ON INVESTIGATIONAL DRUGS 2226 1% 1% 11
7 TRANSLATIONAL CANCER RESEARCH 1888 1% 1% 4
8 INVESTIGATIONAL NEW DRUGS 1869 1% 0% 11
9 LANCET ONCOLOGY 1746 1% 0% 9
10 ANTICANCER RESEARCH 1714 4% 0% 29

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 BEVACIZUMAB 362370 25% 5% 190 Search BEVACIZUMAB Search BEVACIZUMAB
2 OVARIAN CANCER 298335 39% 3% 296 Search OVARIAN+CANCER Search OVARIAN+CANCER
3 VEGF TRAP 114675 1% 26% 11 Search VEGF+TRAP Search VEGF+TRAP
4 AFLIBERCEPT 102347 3% 10% 25 Search AFLIBERCEPT Search AFLIBERCEPT
5 GASTROINTESTINAL PERFORATION 98746 2% 18% 14 Search GASTROINTESTINAL+PERFORATION Search GASTROINTESTINAL+PERFORATION
6 RECURRENT OVARIAN CANCER 83563 3% 10% 21 Search RECURRENT+OVARIAN+CANCER Search RECURRENT+OVARIAN+CANCER
7 TREBANANIB 75421 1% 32% 6 Search TREBANANIB Search TREBANANIB
8 RECURRENT EPITHELIAL OVARIAN CANCER 71083 1% 36% 5 Search RECURRENT+EPITHELIAL+OVARIAN+CANCER Search RECURRENT+EPITHELIAL+OVARIAN+CANCER
9 GI PERFORATION 59712 0% 50% 3 Search GI+PERFORATION Search GI+PERFORATION
10 POLY ADP RIBOSE POLYMERASE INHIBITORS 57900 1% 36% 4 Search POLY+ADP+RIBOSE+POLYMERASE+INHIBITORS Search POLY+ADP+RIBOSE+POLYMERASE+INHIBITORS

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 EISENHAUER, EL , HERZOG, TJ , JACKSON, AL , (2015) EMERGING THERAPIES: ANGIOGENESIS INHIBITORS FOR OVARIAN CANCER.EXPERT OPINION ON EMERGING DRUGS. VOL. 20. ISSUE 2. P. 331 -346 43 66% 9
2 NTANASIS-STATHOPOULOS, I , FOTOPOULOS, G , TZANNINIS, IG , KOTTEAS, EA , (2016) THE EMERGING ROLE OF TYROSINE KINASE INHIBITORS IN OVARIAN CANCER TREATMENT: A SYSTEMATIC REVIEW.CANCER INVESTIGATION. VOL. 34. ISSUE 7. P. 313 -339 48 67% 0
3 DIZON, DS , (2013) WHERE DO ANTIANGIOGENIC AGENTS BELONG IN THE TREATMENT ALGORITHM FOR OVARIAN CANCER?.AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS. VOL. 36. ISSUE 5. P. 519-525 39 76% 1
4 JACKSON, AL , DAVENPORT, SM , HERZOG, TJ , COLEMAN, RL , (2015) TARGETING ANGIOGENESIS: VASCULAR ENDOTHELIAL GROWTH FACTOR AND RELATED SIGNALING PATHWAYS.TRANSLATIONAL CANCER RESEARCH. VOL. 4. ISSUE 1. P. 70 -83 43 64% 1
5 MOROTTI, M , BECKER, CM , MENADA, MV , FERRERO, S , (2013) TARGETING TYROSINE-KINASES IN OVARIAN CANCER.EXPERT OPINION ON INVESTIGATIONAL DRUGS. VOL. 22. ISSUE 10. P. 1265 -1279 45 57% 7
6 MONK, BJ , DALTON, H , FARLEY, JH , CHASE, DM , BENJAMIN, I , (2013) ANTIANGIOGENIC AGENTS AS A MAINTENANCE STRATEGY FOR ADVANCED EPITHELIAL OVARIAN CANCER.CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. VOL. 86. ISSUE 2. P. 161 -175 38 58% 20
7 TEOH, DGK , SECORD, AA , (2011) ANTIANGIOGENIC THERAPIES IN EPITHELIAL OVARIAN CANCER.CANCER CONTROL. VOL. 18. ISSUE 1. P. 31 -43 38 62% 19
8 HAN, ES , WAKABAYASHI, M , LEONG, L , (2013) ANGIOGENESIS INHIBITORS IN THE TREATMENT OF EPITHELIAL OVARIAN CANCER.CURRENT TREATMENT OPTIONS IN ONCOLOGY. VOL. 14. ISSUE 1. P. 22 -33 29 78% 3
9 YU, L , DENG, L , LI, JK , ZHANG, Y , HU, L , (2013) THE PROGNOSTIC VALUE OF VASCULAR ENDOTHELIAL GROWTH FACTOR IN OVARIAN CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS.GYNECOLOGIC ONCOLOGY. VOL. 128. ISSUE 2. P. 391-396 30 63% 26
10 CONTEDUCA, V , KOPF, B , BURGIO, SL , BIANCHI, E , AMADORI, D , DE GIORGI, U , (2014) THE EMERGING ROLE OF ANTI-ANGIOGENIC THERAPY IN OVARIAN CANCER (REVIEW).INTERNATIONAL JOURNAL OF ONCOLOGY. VOL. 44. ISSUE 5. P. 1417 -1424 36 50% 8

Classes with closest relation at Level 1


Rank Class id link
1 17657 BEVACIZUMAB//METASTATIC BREAST CANCER//APATINIB
2 18265 VANDETANIB//NINTEDANIB//CEDIRANIB
3 1615 OVARIAN CANCER//RECURRENT OVARIAN CANCER//PEGYLATED LIPOSOMAL DOXORUBICIN
4 6121 MICROVESSEL DENSITY//ANGIOGENESIS//MICROVESSEL COUNT
5 1475 VEGF//FLT 1//VEGF RECEPTORS
6 28330 COLLAGEN TYPE XI ALPHA 1//PERITONEAL TUMOR SPREAD//PREPARAT BIOTECHNOL UNIT
7 20644 PERITONEOVENOUS SHUNT//MALIGNANT ASCITES//DENVER SHUNT
8 14388 METRONOMIC CHEMOTHERAPY//CIRCULATING ENDOTHELIAL CELLS//METRONOMIC
9 9584 SEROUS TUBAL INTRAEPITHELIAL CARCINOMA//FALLOPIAN TUBE//SEROUS CARCINOMA
10 12629 OVARIAN CANCER//OVARIAN CARCINOMA//CANC MONTREAL

Go to start page